C/VDdb: A multi-omics expression profiling database for a knowledge-driven approach in cardiovascular disease (CVD)

The cardiovascular disease (C/VD) database is an integrated and clustered information resource that covers multi-omic studies (microRNA, genomics, proteomics and metabolomics) of cardiovascular-related traits with special emphasis on coronary artery disease (CAD). This resource was built by mining existing literature and public databases and thereafter manual biocuration was performed. To enable integration of omic data from distinct platforms and species, a specific ontology was applied to tie together and harmonise multi-level omic studies based on gene and protein clusters (CluSO) and mapping of orthologous genes (OMAP) across species. CAD continues to be a leading cause of death in the population worldwide, and it is generally thought to be an age-related disease. However, CAD incidence rates are now known to be highly influenced by environmental factors and interactions, in addition to genetic determinants. With the complexity of CAD aetiology, there is a difficulty in research studies to elucidate general elements compared to other cardiovascular diseases. Data from 92 studies, covering 13945 molecular entries (4353 unique molecules) is described, including data descriptors for experimental setup, study design, discovery-validation sample size and associated fold-changes of the differentially expressed molecular features (p-value<0.05). A dedicated interactive web interface, equipped with a multi-parametric search engine, data export and indexing menus are provided for a user-accessible browsing experience. The main aim of this work was the development of a data repository linking clinical information and molecular differential expression in several CVD-related traits from multi-omics studies (genomics, transcriptomics, proteomics and metabolomics). As an example case of how to query and identify data sets within the database framework and concomitantly demonstrate the database utility, we queried CAD-associated studies and performed a systems-level integrative analysis. URL: www.padb.org/cvd

[1]  S. Kersten,et al.  Peroxisome proliferator-activated receptor α target genes , 2004, Cellular and Molecular Life Sciences CMLS.

[2]  Wang-Soo Lee,et al.  Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions , 2015, PPAR research.

[3]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[4]  J. Deisenhofer,et al.  Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.

[5]  Thomas P Cappola,et al.  Transcriptomic biomarkers of cardiovascular disease. , 2012, Progress in cardiovascular diseases.

[6]  D. Bell Beta-cell rejuvenation with thiazolidinediones. , 2003, The American journal of medicine.

[7]  Chris T. A. Evelo,et al.  CyTargetLinker: A Cytoscape App to Integrate Regulatory Interactions in Network Analysis , 2013, PloS one.

[8]  Jianguo Xia,et al.  Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis , 2016, Current protocols in bioinformatics.

[9]  Jonathan Chaffer,et al.  jQuery Reference Guide: A Comprehensive Exploration of the Popular JavaScript Library , 2007 .

[10]  C. Guillemette,et al.  The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor α and γ Target Gene* , 2003, The Journal of Biological Chemistry.

[11]  M. Fresno,et al.  Peroxisome-proliferator-activated receptor alpha agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. , 2006, The Biochemical journal.

[12]  Joana A. Vidigal,et al.  The biological functions of miRNAs: lessons from in vivo studies. , 2015, Trends in cell biology.

[13]  J. Hengstler,et al.  MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes , 2016, Archives of Toxicology.

[14]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[15]  B. Tian,et al.  RNA‐Seq methods for transcriptome analysis , 2017, Wiley interdisciplinary reviews. RNA.

[16]  Danish Sayed,et al.  MicroRNAs Play an Essential Role in the Development of Cardiac Hypertrophy , 2007, Circulation research.

[17]  D. Bell β-Cell rejuvenation with thiazolidinediones , 2003 .

[18]  Hsien-Da Huang,et al.  miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database , 2015, Nucleic Acids Res..

[19]  Michael Darsow,et al.  ChEBI: a database and ontology for chemical entities of biological interest , 2007, Nucleic Acids Res..

[20]  Michael Müller,et al.  Peroxisome Proliferator-Activated Receptor Alpha Target Genes , 2010, PPAR research.

[21]  Ramon Luengo-Fernandez,et al.  European Cardiovascular Disease Statistics 2017 , 2012 .

[22]  Euan A Ashley,et al.  Performance comparison of whole-genome sequencing platforms , 2011, Nature Biotechnology.

[23]  B. Staels,et al.  Induction of IκBα Expression as a Mechanism Contributing to the Anti-inflammatory Activities of Peroxisome Proliferator-activated Receptor-α Activators* , 2000, The Journal of Biological Chemistry.

[24]  Astrid Gall,et al.  Ensembl 2018 , 2017, Nucleic Acids Res..

[25]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[26]  J. Hou,et al.  Circulating MicroRNA Profiles Differ between Hyperglycemia and Euglycemia in Coronary Heart Disease Patients , 2017, BioMed research international.

[27]  Artemis G. Hatzigeorgiou,et al.  DIANA-miRPath v3.0: deciphering microRNA function with experimental support , 2015, Nucleic Acids Res..

[28]  Bernhard Mlecnik,et al.  CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data , 2013, Bioinform..

[29]  任艳,et al.  胰岛素增敏剂一Thiazolidinediones研究现状 , 2000 .

[30]  R. Murugesan,et al.  CardioGenBase: A Literature Based Multi-Omics Database for Major Cardiovascular Diseases , 2015, PloS one.

[31]  J Auwerx,et al.  Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.

[32]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[33]  Hui Liu,et al.  CADgene: a comprehensive database for coronary artery disease genes , 2010, Nucleic Acids Res..

[34]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[35]  A. Yashin,et al.  Heritability of death from coronary heart disease: a 36‐year follow‐up of 20 966 Swedish twins , 2002, Journal of internal medicine.

[36]  Ronald Aylmer Sir Fisher,et al.  224A: Answer to Question 14 on Combining independent tests of significance. , 1948 .

[37]  R. Deberardinis,et al.  Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? , 2012, Cell.

[38]  F. Slack,et al.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.

[39]  W. Wahli,et al.  PPARα governs glycerol metabolism , 2004 .

[40]  J. Gardin,et al.  Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. , 1994, American journal of epidemiology.

[41]  Antje Chang,et al.  BRENDA in 2017: new perspectives and new tools in BRENDA , 2016, Nucleic Acids Res..

[42]  Ankit Sharma,et al.  In-Cardiome: integrated knowledgebase for coronary artery disease enabling translational research , 2017, Database J. Biol. Databases Curation.

[43]  J. Auwerx,et al.  Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates. , 1992, Journal of lipid research.

[44]  Giovanni Scardoni,et al.  Metscape 2 bioinformatics tool for the analysis and visualization of metabolomics and gene expression data , 2012, Bioinform..

[45]  A. Khera,et al.  Genetics of coronary artery disease: discovery, biology and clinical translation , 2017, Nature Reviews Genetics.

[46]  Alan D. Lopez,et al.  Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015 , 2017, Journal of the American College of Cardiology.

[47]  Ana Kozomara,et al.  miRBase: annotating high confidence microRNAs using deep sequencing data , 2013, Nucleic Acids Res..

[48]  S. J. Lee,et al.  Metabolite Changes Signal Genetic Regulatory Mechanisms for Robust Cell Behavior , 2014, mBio.

[49]  E. Fisher,et al.  Fibrate Therapy: An Update , 2008, Cardiology in review.

[50]  M. Mann,et al.  Quantitative, high-resolution proteomics for data-driven systems biology. , 2011, Annual review of biochemistry.

[51]  Chris T. A. Evelo,et al.  WikiPathways: building research communities on biological pathways , 2011, Nucleic Acids Res..

[52]  L. Berkman,et al.  Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.

[53]  B. Spiegelman PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.

[54]  C. Hermenegildo,et al.  MicroRNA as Crucial Regulators of Gene Expression in Estradiol-Treated Human Endothelial Cells , 2018, Cellular Physiology and Biochemistry.

[55]  Anjali J. Koppal,et al.  Supplementary data: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites , 2010 .

[56]  Michael Lehrke,et al.  The many faces of PPARgamma. , 2005, Cell.

[57]  D. Cooper,et al.  Impact of brief exercise on circulating monocyte gene and microRNA expression: Implications for atherosclerotic vascular disease , 2014, Brain, Behavior, and Immunity.

[58]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[59]  B. Staels,et al.  The protein kinase C signaling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha. , 2004, Molecular endocrinology.

[60]  K. Lage,et al.  Disproportionate Contributions of Select Genomic Compartments and Cell Types to Genetic Risk for Coronary Artery Disease , 2015, PLoS genetics.

[61]  J. Garland THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[62]  H. Husi,et al.  Establishment of a integrative multi-omics expression database CKDdb in the context of chronic kidney disease (CKD) , 2017, Scientific Reports.

[63]  Gary D. Bader,et al.  GeneMANIA Prediction Server 2013 Update , 2013, Nucleic Acids Res..

[64]  C. Bauters,et al.  [Pathophysiology of coronary artery disease]. , 2008, La Revue du praticien.

[65]  A. Oyekan PPARs and their Effects on the Cardiovascular System , 2011, Clinical and experimental hypertension.

[66]  Martin McKee,et al.  Priority actions for the non-communicable disease crisis , 2011, The Lancet.

[67]  Núria Queralt-Rosinach,et al.  DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes , 2015, Database J. Biol. Databases Curation.

[68]  G. Hansson,et al.  The immunology of atherosclerosis , 2017, Nature Reviews Nephrology.

[69]  M. Lazar,et al.  Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.

[70]  B. Staels,et al.  The Protein Kinase C Signaling Pathway Regulates a Molecular Switch between Transactivation and Transrepression Activity of the Peroxisome Proliferator-Activated Receptor α , 2004 .

[71]  Damian Szklarczyk,et al.  The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..

[72]  Renata C. Geer,et al.  The NCBI BioSystems database , 2009, Nucleic Acids Res..

[73]  Michael Lehrke,et al.  The Many Faces of PPARγ , 2005, Cell.

[74]  S. Blankenberg,et al.  Blood-based gene expression tests: promises and limitations. , 2013, Circulation. Cardiovascular genetics.

[75]  B. Staels,et al.  Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. , 1999, Circulation research.

[76]  P. Sime,et al.  PPARγ and the Innate Immune System Mediate the Resolution of Inflammation , 2015, PPAR research.

[77]  John R Yates,et al.  Proteomics by mass spectrometry: approaches, advances, and applications. , 2009, Annual review of biomedical engineering.

[78]  S. Humphries,et al.  Progression of Carotid Intima-Media Thickness as Predictor of Vascular Events: Results from the IMPROVE Study , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[79]  Aldons J. Lusis,et al.  Atherosclerosis : Vascular biology , 2000 .

[80]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[81]  H. Iso Lifestyle and cardiovascular disease in Japan. , 2011, Journal of atherosclerosis and thrombosis.

[82]  R. Beaglehole,et al.  Priority actions for the non-communicable disease crisis – Authors' reply , 2011, The Lancet.

[83]  F. Lönnqvist,et al.  Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1 , 2005, Diabetologia.

[84]  T. Kurtz,et al.  Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin–angiotensin system , 2004, Journal of hypertension.

[85]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[86]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[87]  Christian M. Metallo,et al.  Understanding metabolic regulation and its influence on cell physiology. , 2013, Molecular cell.

[88]  J. Auwerx,et al.  Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1. , 2012, European heart journal.

[89]  Jasmine Chen,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[91]  M. Panchatcharam,et al.  PPARγ and Its Role in Cardiovascular Diseases , 2017, PPAR research.

[92]  Pornpimol Charoentong,et al.  ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..

[93]  P. Libby,et al.  Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.

[94]  R. Evans,et al.  Anatomical Profiling of Nuclear Receptor Expression Reveals a Hierarchical Transcriptional Network , 2006, Cell.

[95]  Ibrahim Emam,et al.  ArrayExpress update—from an archive of functional genomics experiments to the atlas of gene expression , 2008, Nucleic Acids Res..

[96]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[97]  F. Hirsch,et al.  Independent validation test of the vote-counting strategy used to rank biomarkers from published studies. , 2015, Biomarkers in medicine.

[98]  Frank J. Gonzalez,et al.  Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* , 1999, The Journal of Biological Chemistry.

[99]  B. Staels,et al.  Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. , 2000, The Journal of biological chemistry.

[100]  Yifeng Chai,et al.  Cardiovascular Disease Chemogenomics Knowledgebase-guided Target Identification and Drug Synergy Mechanism Study of an Herbal Formula , 2016, Scientific Reports.

[101]  Nobel C. Zong,et al.  Integration of Cardiac Proteome Biology and Medicine by a Specialized Knowledgebase , 2013, Circulation research.

[102]  A. Lamond,et al.  Multidimensional proteomics for cell biology , 2015, Nature Reviews Molecular Cell Biology.

[103]  W. Wahli,et al.  PPARalpha governs glycerol metabolism. , 2004, The Journal of clinical investigation.

[104]  E. Suchman,et al.  The American Soldier: Adjustment During Army Life. , 1949 .

[105]  N. Marx,et al.  Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. , 2004, Circulation research.

[106]  C. Guillemette,et al.  The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. , 2003, The Journal of biological chemistry.

[107]  F. Pontén,et al.  The Human Protein Atlas—a tool for pathology , 2008, The Journal of pathology.